Il-17-mediated autoimmunity and inflammation are closely linked with the administration of anti-PD-1/PD-L1 or anti-CTLA-4 antibodies in the therapeutic management of malignant neoplasms (14). The gene discussed is PDCD1; the disease is Autoimmunity.